Literature DB >> 19282331

Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom.

F Kate Gould1, Richard Brindle, Paul R Chadwick, Adam P Fraise, Simon Hill, Dilip Nathwani, Geoff L Ridgway, Michael J Spry, Rod E Warren.   

Abstract

These evidence-based guidelines are an updated version of those published in 2006. They have been produced after a literature review of the treatment and prophylaxis of methicillin-resistant Staphylococcus aureus (MRSA). The guidelines aim to complement those recently published for the antibiotic treatment of common and emerging community-onset MRSA infections in the UK. The guidelines have reviewed and updated, where appropriate, previous recommendations, taking into account any changes in the UK epidemiology of MRSA, ongoing national surveillance data and the value of new antistaphylococcal agents licensed for use in UK practice. Emerging therapies that have not been licensed for UK use are not reviewed, but their future potential role has been mentioned where deemed appropriate. Recommendations are given for the treatment of common infections caused by MRSA, elimination of MRSA from carriage sites and prophylaxis of surgical site infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19282331     DOI: 10.1093/jac/dkp065

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  41 in total

1.  [In vitro studies on human ovarian contractility (author's transl)].

Authors:  H Okamura; T Okazaki; A Nakajima
Journal:  Nihon Funin Gakkai Zasshi       Date:  1975-10

2.  Pharmacokinetic-pharmacodynamic evaluation of daptomycin, tigecycline, and linezolid versus vancomycin for the treatment of MRSA infections in four western European countries.

Authors:  A Canut; A Isla; C Betriu; A R Gascón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-02-28       Impact factor: 3.267

3.  Audit of treatment of Staphylococcus aureus bacteraemia.

Authors:  V Wong; R Wariyar; V Weston; W J Olver; E Youngs; A Hussain; N Perera; A Swann
Journal:  Clin Med (Lond)       Date:  2010-06       Impact factor: 2.659

Review 4.  MRSA: treating people with infection.

Authors:  Nikolas Rae; Anna Jarchow-MacDonald; Dilip Nathwani; Charis Ann Marwick
Journal:  BMJ Clin Evid       Date:  2016-02-16

5.  Economic evaluation of treatment for MRSA complicated skin and soft tissue infections in Glasgow hospitals.

Authors:  R A Seaton; S Johal; J E Coia; N Reid; S Cooper; B L Jones
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-08-31       Impact factor: 3.267

Review 6.  MRSA: treating people with infection.

Authors:  Dilip Nathwani; Peter Garnet Davey; Charis Ann Marwick
Journal:  BMJ Clin Evid       Date:  2010-10-28

Review 7.  Clinical management of Staphylococcus aureus bacteremia: a review.

Authors:  Thomas L Holland; Christopher Arnold; Vance G Fowler
Journal:  JAMA       Date:  2014-10-01       Impact factor: 56.272

Review 8.  Gloves, gowns and masks for reducing the transmission of meticillin-resistant Staphylococcus aureus (MRSA) in the hospital setting.

Authors:  Jesús López-Alcalde; Marta Mateos-Mazón; Marcela Guevara; Lucieni O Conterno; Ivan Solà; Sheila Cabir Nunes; Xavier Bonfill Cosp
Journal:  Cochrane Database Syst Rev       Date:  2015-07-16

9.  Vancomycin Area Under the Curve and Acute Kidney Injury: A Meta-analysis.

Authors:  Doaa M Aljefri; Sean N Avedissian; Nathaniel J Rhodes; Michael J Postelnick; Kevin Nguyen; Marc H Scheetz
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 9.079

10.  Pharmacoeconomic advantages of oral minocycline for the therapy of methicillin-resistant Staphylococcus aureus (MRSA) skin and soft tissue infections (SSTIs).

Authors:  B A Cunha
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-18       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.